Lexicon Genetics Incorporated (NASDAQ:LEXG) today presented results from the company’s genetic screen to identify proteins involved in blood vessel formation and organization. These results were delivered in both a presentation and poster titled Large Scale Genetic Screen to Identify Genes Implicated in Vascular Biology in Mammals at IBC Life Sciences’ meeting, Ocular Anti-angiogenesis: Translating Preclinical Indications to Successful Clinical Development.

“Our screening platform is unique in the field of ophthalmology and has proven extremely useful in the identification of promising potential drug targets for ocular diseases,” stated Dennis S. Rice, Ph.D., Director of Ophthalmology at Lexicon Genetics, and lead author presenting the work. “Using our knock-out technology, we are able to study the results of blocking gene function in vivo, so that we may choose targets for ocular drug discovery and development with desired therapeutic profiles in mind.”

The research highlighted in today’s presentation demonstrates the power of these technologies in identifying new targets that produce anti-angiogenic effects similar to those caused by blocking vascular endothelial growth factor (VEGF). This research is aimed at the development of novel therapeutics for the treatment of age-related macular degeneration, diabetic retinopathy, and other diseases, including cancer, in which angiogenesis plays a role.

With its unique ophthalmic-specific screening platform, Lexicon has examined the functions of over 4,000 genes using knockout mice from the Company’s Genome5000(TM) program and has identified proteins involved in retinal degeneration, glaucoma, dry eye and ocular inflammation. The focus of the company’s presentation at the conference is the discovery platform used to elucidate genes that affect vascular biology. Vascular diseases represent one of the most sight-threatening conditions in ophthalmology.

About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexicon-genetics.com/ .

Related Health News:

1. Curidium Discovers Significantly Different Patient Subgroups in Schizophrenia and Bipolar Disorder Curidium Medica plc, (LSE: CUR) has discovered four unique and statistically significantly different subgroups of schizophrenia/bipolar disorder patients based on their gene expression profiles. Using...
2. Metabolex Shows MBX-102 JNJ-39659100 Reduces Inflammation in Preclinical Models of Diabetes Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced the results from a...
3. Lux Biosciences Receives Orphan Drug Designation from FDA Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, has announced that the U.S. Food and Drug Administration (FDA)...
4. Anti-Aging Medical Headlines of 2006 Lead to Major Biomedical Advancements in 2007 2006 was a banner year filled with many significant biomedical advancements and research findings with implications for enhancing the quality, as well as expanding the...
5. OrthoGlide Medial Knee Implant Reports Over 200 Implants Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer has recently announced that over 200 implants have been completed in the United States using...